Analyzing Inhibitor Therapeutics (OTCMKTS:INTI) and Science 37 (NASDAQ:SNCE)

Science 37 (NASDAQ:SNCEGet Rating) and Inhibitor Therapeutics (OTCMKTS:INTIGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Valuation & Earnings

This table compares Science 37 and Inhibitor Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Science 37 $59.60 million 6.19 -$560,000.00 N/A N/A
Inhibitor Therapeutics N/A N/A -$300,000.00 N/A N/A

Inhibitor Therapeutics has lower revenue, but higher earnings than Science 37.


This table compares Science 37 and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Science 37 N/A -95.04% -42.91%
Inhibitor Therapeutics N/A N/A -280.76%

Risk & Volatility

Science 37 has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Science 37 and Inhibitor Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Science 37 0 0 4 0 3.00
Inhibitor Therapeutics 0 0 0 0 N/A

Science 37 presently has a consensus target price of $16.00, indicating a potential upside of 403.14%. Given Science 37’s higher probable upside, research analysts plainly believe Science 37 is more favorable than Inhibitor Therapeutics.

Institutional and Insider Ownership

46.1% of Science 37 shares are held by institutional investors. 4.4% of Science 37 shares are held by insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Science 37 beats Inhibitor Therapeutics on 6 of the 9 factors compared between the two stocks.

About Science 37 (Get Rating)

Science 37 Holdings, Inc. engages in the development of a technology platform to enable agile clinical trials and specialized networks to orchestrate trial execution. The company develops agile clinical trial operating system that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, medical device, and biotech companies. The company was formerly known as Science 37, Inc. and changed its name to Science 37 Holdings, Inc. in October 2021. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

About Inhibitor Therapeutics (Get Rating)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with's FREE daily email newsletter.